Search

Your search keyword '"Tamari, Roni"' showing total 766 results

Search Constraints

Start Over You searched for: Author "Tamari, Roni" Remove constraint Author: "Tamari, Roni"
766 results on '"Tamari, Roni"'

Search Results

4. Donor-Derived Malignancy and Transplantation Morbidity: Risks of Patient and Donor Genetics in Allogeneic Hematopoietic Stem Cell Transplantation

5. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group

6. Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial

7. Association between busulfan exposure and survival in patients undergoing a CD34+ selected stem cell transplantation

8. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

9. Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemia

11. Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant

14. The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT

15. Antithymocyte globulin exposure in CD34+ T-cell–depleted allogeneic hematopoietic cell transplantation

16. Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study

17. Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation

18. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy

20. Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant

23. Development and validation of a disease risk stratification system for patients with haematological malignancies: a retrospective cohort study of the European Society for Blood and Marrow Transplantation registry

25. High progression-free survival after intermediate intensity double unit cord blood transplantation in adults

27. Survival following allogeneic transplant in patients with myelofibrosis

28. Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease

29. Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis

30. Phase 2 Trial of Ruxolitinib Cream for Chronic Cutaneous GvHD

31. Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT).

32. Budesonide Use for Grade 2 Gastrointestinal Graft-Versus-Host Disease after Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis

33. High Progression-Free Survival with Low Relapse Rates after Double-Unit Cord Blood Transplantation in Patients with High-Risk AML

34. Early CD4 and B Cell Immune Reconstitution As Predictors of Outcomes in T Cell Depleted Allogeneic Hematopoietic Cell Transplantation

35. Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulin

36. Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation

37. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation

38. Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor

40. Impact of geriatric vulnerabilities on allogeneic hematopoietic cell transplantation outcomes in older patients with hematologic malignancies

41. Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation

42. Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis

44. Burden and impact of multifactorial geriatric syndromes in allogeneic hematopoietic cell transplantation for older adults

45. Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial

47. Donor-derived malignancy and transplant morbidity: Risks of patient and donor genetics in allogeneic hematopoietic stem cell transplant

48. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy

50. Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation

Catalog

Books, media, physical & digital resources